Anixa Biosciences (NASDAQ:ANIX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Anixa Biosciences (NASDAQ:ANIX) from a sell rating to a hold rating in a research report report published on Saturday.

Several other research firms also recently weighed in on ANIX. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, February 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Anixa Biosciences currently has a consensus rating of “Hold” and a consensus target price of $9.00.

Anixa Biosciences Stock Up 4.6%

NASDAQ:ANIX opened at $2.98 on Friday. The stock has a fifty day simple moving average of $3.05 and a 200 day simple moving average of $3.56. The firm has a market capitalization of $99.47 million, a price-to-earnings ratio of -8.51 and a beta of 0.48. Anixa Biosciences has a 1-year low of $2.33 and a 1-year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. Equities analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Buying and Selling

In other Anixa Biosciences news, Director Arnold M. Baskies acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, January 28th. The stock was purchased at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the transaction, the director owned 135,000 shares of the company’s stock, valued at $410,400. The trade was a 8.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in shares of Anixa Biosciences in the fourth quarter worth approximately $161,000. Millennium Management LLC purchased a new position in Anixa Biosciences during the fourth quarter valued at approximately $38,000. 683 Capital Management LLC purchased a new position in Anixa Biosciences during the fourth quarter valued at approximately $355,000. Cetera Investment Advisers acquired a new position in Anixa Biosciences in the 4th quarter valued at approximately $35,000. Finally, ExodusPoint Capital Management LP acquired a new position in Anixa Biosciences in the 4th quarter valued at approximately $293,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.